Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1964 Feb;43(2):160–166. doi: 10.1172/JCI104900

Activation Product, Factor IX, Serum Thrombotic Accelerator Activity, and Serum-induced Thrombosis*

Daniel Deykin 1,2, Stanford Wessler 1,2
PMCID: PMC289509  PMID: 14162524

Full text

PDF
160

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BACHMANN F., DUCKERT F., KOLLER F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh. 1958 May 1;2(1-2):24–38. [PubMed] [Google Scholar]
  2. DUCKERT F. The prephase accelerator. Present status. Thromb Diath Haemorrh. 1961 Sep 1;6:254–260. [PubMed] [Google Scholar]
  3. HARDISTY R. M. A naturally occurring inhibitor of Christmas factor (factor IX). Thromb Diath Haemorrh. 1962 Oct 1;8:67–81. [PubMed] [Google Scholar]
  4. HARDISTY R. M., MACPHERSON J. C. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh. 1962 May 15;7:215–228. [PubMed] [Google Scholar]
  5. HENDERSON E. S., RAPAPORT S. L. The thrombotic activity of activation product. J Clin Invest. 1962 Feb;41:235–244. doi: 10.1172/JCI104475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. LEWIS F. J., NOUR-ELDIN F. Factor IX in intravascular and extravascular blood coagulation. Blood. 1962 Jul;20:41–50. [PubMed] [Google Scholar]
  7. MUSTARD J. F. [The serum defect in Christmas disease]. Acta Haematol. 1959 Jun;21:321–328. doi: 10.1159/000205709. [DOI] [PubMed] [Google Scholar]
  8. OWREN P. A., AAS K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3(3):201–208. doi: 10.3109/00365515109060600. [DOI] [PubMed] [Google Scholar]
  9. QUICK A. J. The hereditary haemorrhagic diseases: their classification and diagnosis. Br Med J. 1959 Apr 25;1(5129):1059–1062. doi: 10.1136/bmj.1.5129.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. RAPAPORT S. I., SCHIFFMAN S., PATCH M. J., AMES S. B. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood. 1963 Feb;21:221–236. [PubMed] [Google Scholar]
  11. SPAET T. H., KROPATKIN M. Effect of intravenous soy bean phosphatides on blood coagulation in rabbits. Proc Soc Exp Biol Med. 1957 Jul;95(3):492–495. doi: 10.3181/00379727-95-23263. [DOI] [PubMed] [Google Scholar]
  12. SPAET T. H. Studies on the in vivo behavior of blood coagulation product I in rats. Thromb Diath Haemorrh. 1962 Nov 15;8:276–285. [PubMed] [Google Scholar]
  13. WESSLER S., REIMER S. M., SHEPS M. C. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol. 1959 Nov;14:943–946. doi: 10.1152/jappl.1959.14.6.943. [DOI] [PubMed] [Google Scholar]
  14. WESSLER S., REIMER S. M. The role of human coagulation factors in serum-induced thrombosis. J Clin Invest. 1960 Feb;39:262–265. doi: 10.1172/JCI104036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. WESSLER S. Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. J Clin Invest. 1955 Apr;34(4):647–651. doi: 10.1172/JCI103114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. WESSLER S. Thrombosis in the presence of vascular stasis. Am J Med. 1962 Nov;33:648–666. doi: 10.1016/0002-9343(62)90244-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES